MBIA Inc. heads into its Q1 2026 earnings release with short sellers quietly stepping back — even as the stock races higher.
Short sellers have been reducing positions steadily. SI % FF has fallen from roughly 3.7% in mid-April to 3.5% now, a decline of nearly 2% over the past week alone. Borrow conditions reflect the retreat: cost to borrow is a modest 0.65%, and availability remains loose, with just 7.6% of available shares currently lent out — well below the 52-week peak of 34.7%. That combination points to a lending market far removed from any squeeze dynamic. The ORTEX short score has also eased, slipping from 47.6 on April 23 to 43.2 today, further confirming that bearish conviction has been fading into the report.
Options positioning reinforces the same message. The put/call ratio is running below its 20-day average at 0.46 — nearly a full standard deviation beneath the norm — suggesting that options traders are leaning more toward upside exposure than downside protection ahead of the print. That is a relatively calm read for a stock up nearly 10% on the week and 5% on the day.
The stock's recent run has outpaced most of its correlated peers. Closest peer UFCS is up 16% on the week, so some of the insurance-sector tailwind is broad, but 's 9.4% weekly gain still stands out. The lone active analyst on the name — Keefe, Bruyette & Woods — trimmed its price target from $8.50 to $7.50 back in March while maintaining an Outperform rating, citing ongoing uncertainty in MBIA's runoff book. The $7.25 consensus target sits roughly 13% above the current $6.39 close. That gap is meaningful but has narrowed sharply as the stock rallied.
The insider picture adds a note of caution. In early March, CEO William Fallon sold nearly 40,000 shares at $6.88, alongside smaller sales by multiple vice presidents — a broad-based reduction at price levels slightly above where the stock now trades. The net 90-day insider position is a positive $4.5 million, largely driven by an equity award to a VP rather than open-market buying, which tempers the bullish read. Q1 results already hit the wire after market close on May 7, showing revenue of $24 million — a significant beat against a $6 million estimate — while adjusted EPS of -$0.16 missed by a cent. The earnings release will test whether that revenue surprise is enough to sustain the stock above levels where insiders recently chose to sell.
See the live data behind this article on ORTEX.
Open MBI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
